טוען...
Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status
The clinical benefit of anthracyclines has been connected to HER2 status, TOP2A status and centromere 17 copy numbers (CEN‐17). Data from a clinical trial randomizing patients to anthracyclines was used to assess whether the number of CEN‐17 in breast cancers may predict incremental responsiveness t...
שמור ב:
| הוצא לאור ב: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528381/ https://ncbi.nlm.nih.gov/pubmed/22153616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2011.11.006 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|